Lucid Diagnostics Inc. Research and Development Expense
Lucid Diagnostics Inc. (LUCD) reported Research and Development Expense of $1.19 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-12
- Lucid Diagnostics Inc. research and development expense for the quarter ending 2026-06-30 was $1.19M, a 5.02% decline year-over-year.
- Lucid Diagnostics Inc. research and development expense for the quarter ending 2026-03-31 was $1.21M, a 15.55% decline year-over-year.
- Lucid Diagnostics Inc. research and development expense for the quarter ending 2025-12-31 was $1.72M, a 18.58% increase year-over-year.
- Lucid Diagnostics Inc. research and development expense for the quarter ending 2025-09-30 was $1.27M, a 23.65% decline year-over-year.
- Lucid Diagnostics Inc. research and development expense for fiscal 2025 was $5.68M, a 5.24% decline from fiscal 2024.
- Lucid Diagnostics Inc. research and development expense for fiscal 2024 was $5.99M, a 17.37% decline from fiscal 2023.
- Lucid Diagnostics Inc. research and development expense for fiscal 2023 was $7.25M, a 35.58% decline from fiscal 2022.
- Lucid Diagnostics Inc. research and development expense for fiscal 2022 was $11.26M, a 21.10% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.19M 10-Q · filed 2026-08-12 | $2.40M 10-Q · filed 2026-08-12 | $4.12M derived: sum of 3 quarters · filed 2026-08-12 | $5.39M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2026-03-31 | $1.21M 10-Q · filed 2026-05-13 | $2.93M derived: sum of 2 quarters · filed 2026-05-13 | $4.20M derived: sum of 3 quarters · filed 2026-05-13 | $5.46M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-12-31 | $1.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $3.00M derived: sum of 2 quarters · filed 2026-03-25 | $4.25M derived: sum of 3 quarters · filed 2026-08-12 | $5.68M 10-K · filed 2026-03-25 | ||||
| 2025-09-30 | $1.27M 10-Q · filed 2025-11-12 | $2.53M derived: sum of 2 quarters · filed 2026-08-12 | $3.96M 10-Q · filed 2025-11-12 | $5.41M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-06-30 | $1.25M 10-Q · filed 2026-08-12 | $2.68M 10-Q · filed 2026-08-12 | $4.14M derived: sum of 3 quarters · filed 2026-08-12 | $5.80M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-03-31 | $1.43M 10-Q · filed 2026-05-13 | $2.88M derived: sum of 2 quarters · filed 2026-05-13 | $4.55M derived: sum of 3 quarters · filed 2026-05-13 | $5.92M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | $1.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $3.12M derived: sum of 2 quarters · filed 2026-03-25 | $4.49M derived: sum of 3 quarters · filed 2026-03-25 | $5.99M 10-K · filed 2026-03-25 | ||||
| 2024-09-30 | $1.67M 10-Q · filed 2025-11-12 | $3.04M derived: sum of 2 quarters · filed 2025-11-12 | $4.54M 10-Q · filed 2025-11-12 | $6.46M derived: sum of 4 quarters · filed 2025-11-12 | ||||
| 2024-06-30 | $1.37M 10-Q · filed 2025-08-12 | $2.87M 10-Q · filed 2025-08-12 | $4.79M derived: sum of 3 quarters · filed 2025-08-12 | $6.41M derived: sum of 4 quarters · filed 2025-08-12 | ||||
| 2024-03-31 | $1.50M 10-Q · filed 2025-05-13 | $3.42M derived: sum of 2 quarters · filed 2025-05-13 | $5.03M derived: sum of 3 quarters · filed 2025-05-13 | $6.86M derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | $1.92M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $3.53M derived: sum of 2 quarters · filed 2025-03-24 | $5.36M derived: sum of 3 quarters · filed 2025-03-24 | $7.25M 10-K · filed 2025-03-24 | ||||
| 2023-09-30 | $1.61M 10-Q · filed 2024-11-12 | $3.44M derived: sum of 2 quarters · filed 2024-11-12 | $5.33M 10-Q · filed 2024-11-12 | $7.78M derived: sum of 4 quarters · filed 2024-11-12 | ||||
| 2023-06-30 | $1.83M 10-Q · filed 2024-08-12 | $3.72M 10-Q · filed 2024-08-12 | $4.11M 10-Q · filed 2023-08-14 | $6.16M derived: sum of 3 quarters · filed 2024-08-12 | $8.87M derived: sum of 4 quarters · filed 2024-08-12 | |||
| 2023-03-31 | $1.89M 10-Q · filed 2024-05-13 | $2.28M 10-Q · filed 2023-05-15 | $4.33M derived: sum of 2 quarters · filed 2024-05-13 | $7.04M derived: sum of 3 quarters · filed 2024-05-13 | $10.48M derived: sum of 4 quarters · filed 2024-05-13 | |||
| 2022-12-31 | $2.44M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $5.15M derived: sum of 2 quarters · filed 2024-03-25 | $8.59M derived: sum of 3 quarters · filed 2024-03-25 | $11.26M 10-K · filed 2024-03-25 | $11.47M 10-K · filed 2023-03-14 | |||
| 2022-09-30 | $2.70M 10-Q · filed 2023-11-13 | $6.14M derived: sum of 2 quarters · filed 2023-11-13 | $8.81M 10-Q · filed 2023-11-13 | $9.02M 10-Q · filed 2022-11-14 | $12.51M derived: sum of 4 quarters · filed 2023-11-13 | |||
| 2022-06-30 | $3.44M 10-Q · filed 2023-08-14 | $6.32M 10-Q · filed 2023-08-14 | $9.80M derived: sum of 3 quarters · filed 2023-08-14 | $11.99M derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2022-03-31 | $2.88M 10-Q · filed 2023-05-15 | $6.36M derived: sum of 2 quarters · filed 2023-05-15 | $8.55M derived: sum of 3 quarters · filed 2023-05-15 | $10.43M derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | $3.48M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $5.67M derived: sum of 2 quarters · filed 2023-03-14 | $7.54M derived: sum of 3 quarters · filed 2023-03-14 | $9.30M 10-K · filed 2023-03-14 | ||||
| 2021-09-30 | $2.19M 10-Q · filed 2022-11-14 | $2.19M 10-Q · filed 2021-11-23 | $4.06M derived: sum of 2 quarters · filed 2022-11-14 | $5.81M 10-Q · filed 2022-11-14 | $5.81M 10-Q · filed 2021-11-23 | $7.64M derived: sum of 4 quarters · filed 2022-11-14 | ||
| 2021-06-30 | $1.87M 10-Q · filed 2022-08-15 | $3.63M 10-Q · filed 2022-08-15 | $5.45M derived: sum of 3 quarters · filed 2022-08-15 | $6.67M derived: sum of 4 quarters · filed 2022-08-15 | ||||
| 2021-03-31 | $1.75M 10-Q · filed 2022-05-16 | $3.58M derived: sum of 2 quarters · filed 2022-05-16 | $4.79M derived: sum of 3 quarters · filed 2022-05-16 | |||||
| 2020-12-31 | $1.83M derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-06 | $3.04M derived: sum of 2 quarters · filed 2022-04-06 | $5.44M 10-K · filed 2022-04-06 | |||||
| 2020-09-30 | $1.22M 10-Q · filed 2021-11-23 | $3.62M 10-Q · filed 2021-11-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KORU Medical Systems, Inc. (KRMD) | United States | $0.151B | -106.78 |
| Profound Medical Corp. (PROF) | $0.206B | -7.37 | |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |
| Apyx Medical Corp (APYX) | United States | $0.120B | -21.85 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| Microbot Medical Inc. (MBOT) | $0.089B | -7.97 | |
| LENSAR, Inc. (LNSR) | United States | $0.087B | 2.02 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| SkinHealth Systems Inc. (SKIN) | United States | $0.086B | -3.17 |